FPFederico Perdomo-Celis

Federico Perdomo-Celis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Federico Perdomo-Celis has a total of 212 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nur77 Is Associated With Polyfunctional Properties in Virus‐Specific Human CD8 + T Cells

    by Fabiola Martel, Daniel Rincón, Caroline Passaes, Leonardo Arévalo, Marcela Torres, Natalia Ramirez, Carlos F. Narváez, Jessica F. Toro, Otto Sussmann, Manuel A. Franco, et al.

    Human CD8 + T cells undergo significant metabolic and transcriptional shifts during activation and differentiation. The orphan nuclear receptor Nur77 plays a role in modulating these processes and has been linked to T cell dysfunction. However, few studies have addressed its role in the memory potential and functionality of human CD8 + T cells. Here, we evaluated the expression of Nur77 in human CD8 + T cells, focusing on its relationship with their differentiation profile and functionality. Our findings indicate that Nur77 is associated with an early‐differentiated, T cell factor 1 + (TCF‐1 + ) memory‐like phenotype in both total and virus‐specific human CD8 + T cells across contexts of acute resolved or chronic viral infection and vaccination. Nur77 expression was associated with cytokine polyfunctionality and increased proliferative capacity in long‐lived antigen‐responsive cells. Moreover, the modulation of Nur77 activity in vitro enhanced the functionality of chronic human immunodeficiency virus (HIV) and hepatitis B virus (HBV)‐specific CD8 + T cells. These results suggest that Nur77 is associated with polyfunctional properties in virus‐specific CD8 + T cell responses in humans. In addition, this study provides insights into novel strategies for enhancing CD8 + T cell functionality in settings of chronic antigen stimulation.


  • Open Access

    Virus-like Particles and Spectral Flow Cytometry for Identification of Dengue Virus-Specific B Cells in Mice and Humans

    by Katherine Segura, Fabiola Martel, Manuel A. Franco, Federico Perdomo-Celis, Carlos F. Narváez

    Severe dengue virus (DENV) infections are associated with circulating non-neutralizing antibodies generated during heterotypic infections. Although antibodies are key mediators of both protection and pathogenesis, the specific dynamics of B cells (Bc) and their antibody responses remain insufficiently characterized due to limited methods of identifying DENV-specific Bc (DENV-Bc) and the absence of animal models resembling the human disease. Here, we developed a spectral flow cytometry assay employing biotinylated virus-like particles (VLPs) to detect DENV-Bc in C57BL/6 mice and children hospitalized with dengue. DENV-1 and DENV-2 VLPs were biotinylated, and the efficiency of biotin incorporation was assessed with an HABA-avidin assay and ELISA. Serotype specificity and optimal binding conditions were confirmed using hybridomas 4G2 (pan-flavivirus) and 3H5-1 (DENV-2 specific). Fluorescent agglutimers were subsequently generated by coupling biotinylated VLPs to streptavidin–fluorochrome complexes. Splenocytes from intraperitoneally DENV-infected mice and peripheral blood mononuclear cells (PBMCs) from naturally infected pediatric patients were stained with these VLPs and Bc-lineage markers. Biotinylated VLPs bound specifically to hybridomas, and this binding was competitively inhibited by unlabeled VLPs. After secondary DENV challenge, VLPs identified DENV-specific class-switched plasmablasts in mice. Circulating DENV-specific plasmablasts were also detected in children, with agglutimers enabling the discrimination of serotype-specific and cross-reactive responses in primary and secondary infections. This VLP-based approach represents a scalable platform to investigate the protective and pathogenic roles of DENV-Bc in infection and vaccination.


  • Open Access

    Impact of rosuvastatin on the memory potential and functionality of CD8+ T cells from people with HIV

    by Federico Perdomo-Celis, Caroline Passaes, Valérie Monceaux, Olivier Lambotte, Dominique Costagliola, Mathieu F. Chevalier, Laurence Weiss, Asier Sáez-Cirión


  • Open Access

    Benefits of INSTI‐Based Regimens in a Real‐World Setting of People Living With HIV‐1 in Colombia

    by Juan C. Alzate-Angel, John D. Loaiza, Federico Perdomo-Celis, Juan C. Hernandez, Ximena Galindo-Orrego, Mónica Mantilla-Suárez, Fanny Guzman, Juan Carlos Cataño, Francisco J. Diaz, María T. Rugeles, et al.

    Objective: The objective is to compare the clinical, virological, and immunological characteristics of people living with HIV‐1 who were treated with first‐line integrase inhibitors (INSTIs) versus those treated with other antiretrovirals. Methods: This is a descriptive observational, retrospective, two‐center study. We selected individuals who began antiretroviral therapy (ART) within the first year of diagnosis and who had received at least 1 year of treatment. Their therapy consisted of two nucleoside/nucleotide reverse transcriptase inhibitors, along with a third medication (INSTI, nonnucleoside reverse transcriptase inhibitor (NNRTI), or protease inhibitor). The primary comparison was between individuals who initiated ART containing INSTIs and those who initiated ART containing NNRTIs or protease inhibitors. We evaluated clinical outcomes, residual viral load, circulating proviral DNA, inflammation, and cardiovascular risk markers, T cell count and phenotype, and the frequency of HIV‐specific T cells. Results: Individuals who received INSTI‐based regimens started treatment at a more advanced disease stage and had a significantly shorter ART duration at study inclusion than individuals who did not receive INSTI‐based ART. Individuals receiving INSTIs achieved CD4 + T cell counts at levels comparable to those within the non‐INSTI group, as well as similar levels of virological, immunological, and cardiovascular markers. Nonetheless, those in the INSTI‐based group had higher CD8 + T cell counts and lower CD4/CD8 ratios, as well as lower high‐density lipoprotein levels. Conclusions: INSTI‐based regimens offer benefits to Colombian people living with HIV‐1, who are starting ART, including improved and faster virological and CD4 + T cell reconstitution. This occurs despite treatment initiation for advanced disease.


  • Top Cited Papers
    Open Access

    Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells

    by Asier Sáez-Cirión, Anne-Claire Mamez, Véronique Avettand-Fenoel, Mitja Nabergoj, Caroline Passaes, Paul Thoueille, Laurent Decosterd, Maxime Hentzien, Federico Perdomo-Celis, Maria Salgado, et al.

    HIV cure has been reported for five individuals who received allogeneic hematopoietic stem cell transplant (allo-HSCT) from CCR5Δ32 homozygous donors. In contrast, viral rebound has occurred in other people living with HIV who interrupted antiretroviral treatment after receiving allo-HSCT, mostly from wild-type CCR5 donors. Here, we report the case of a male who has achieved durable HIV remission following allo-HSCT from an unrelated HLA-matched (9/10 matching for HLA-A, -B, -C, -DRB1 and -DQB1 alleles) wild-type CCR5 donor to treat an extramedullary myeloid tumor. To date, plasma viral load has remained undetectable for 32 months after the interruption of antiretroviral treatment. Treatment with ruxolitinib has been maintained during this period to treat chronic graft versus host disease. Low levels of proviral DNA were detected sporadically post-allo-HSCT, including defective but not intact HIV DNA. No virus could be amplified in cultures of CD4 + T cells obtained post antiretroviral treatment interruption, while CD4 + T cells remained susceptible to HIV-1 infection in vitro. Decline of HIV antibodies and undetectable HIV-specific T cell responses further corroborate the absence of viral rebound after antiretroviral treatment interruption. These results suggest that HIV remission could be achieved in the context of allo-HSCT with wild-type CCR5.


  • Open Access

    Evaluation of Four Humanized NOD-Derived Mouse Models for Dengue Virus-2 Infection

    by Hernando Gutierrez-Barbosa, Sandra Medina-Moreno, Federico Perdomo-Celis, Harry Davis, Joel V. Chua, Juan C. Zapata

    Dengue is a significant public health problem with no specific viral treatment. One of the main challenges in studying dengue is the lack of adequate animal models recapitulating human immune responses. Most studies on humanized mice use NOD-scid IL2R gamma null (NSG) mice, which exhibit poor hematopoiesis for some cell populations. This study compares three humanized (hu) NOD-derived mouse models for dengue virus-2 (DENV-2) infection in the context of human cytokine expression. Three mouse strains (hu-NSG, hu-EXL, and hu-SGM3) received xenotransplants of human CD34+ fetal cord blood cells from a single donor, and one mouse strain received human peripheral blood mononuclear cells (hu-SGM3-PBMCs). All models exhibited infectious viruses in blood confirmed by plaque assay, but mice expressing human cytokines showed higher viremia compared to conventional NSG mice. The hu-SGM3-PBMCs model developed lethal infections, showing a significant increase in viremia and clinical signs. A detectable human cytokine response was observed in all the DENV-2-infected humanized mouse models. In conclusion, humanized NOD-derived mouse models expressing human cytokines offer a relevant platform for the study of dengue pathogenesis and antiviral therapies.


  • Open Access

    Update on Early-Life T Cells: Impact on Oral Rotavirus Vaccines

    by Catherine Montenegro, Federico Perdomo-Celis, Manuel A. Franco

    Rotavirus infection continues to be a significant public health problem in developing countries, despite the availability of several vaccines. The efficacy of oral rotavirus vaccines in young children may be affected by significant immunological differences between individuals in early life and adults. Therefore, understanding the dynamics of early-life systemic and mucosal immune responses and the factors that affect them is essential to improve the current rotavirus vaccines and develop the next generation of mucosal vaccines. This review focuses on the advances in T-cell development during early life in mice and humans, discussing how immune homeostasis and response to pathogens is established in this period compared to adults. Finally, the review explores how this knowledge of early-life T-cell immunity could be utilized to enhance current and novel rotavirus vaccines.


  • Top Cited Papers
    Open Access

    Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8+ T-cells

    by Caroline Passaes, Delphine Desjardins, Anaïs Chapel, Valérie Monceaux, Julien Lemaitre, Adeline Mélard, Federico Perdomo-Celis, Cyril Planchais, Maël Gourvès, Nastasia Dimant, et al.

    HIV remission can be achieved in some people, called post-treatment HIV controllers, after antiretroviral treatment discontinuation. Treatment initiation close to the time of infection was suggested to favor post-treatment control, but the circumstances and mechanisms leading to this outcome remain unclear. Here we evaluate the impact of early (week 4) vs. late (week 24 post-infection) treatment initiation in SIVmac251-infected male cynomolgus macaques receiving 2 years of therapy before analytical treatment interruption. We show that early treatment strongly promotes post-treatment control, which is not related to a lower frequency of infected cells at treatment interruption. Rather, early treatment favors the development of long-term memory CD8+ T cells with enhanced proliferative and SIV suppressive capacity that are able to mediate a robust secondary-like response upon viral rebound. Our model allows us to formally demonstrate a link between treatment initiation during primary infection and the promotion of post-treatment control and provides results that may guide the development of new immunotherapies for HIV remission.


  • Frequency, Markers and Costs of Secondary Bacterial Infection in Pediatric Dengue

    by Doris Salgado, Jennifer M. Silva, Arnold Salcedo, Paula Ximena Losada, Angela P. Niño, Milton Molano, Juan M. Bermeo, Ruby Restrepo, Federico Perdomo-Celis, Carlos F. Narváez, et al.

    Background: Secondary bacterial infection (SBI) occurs in a proportion of individuals with dengue and results in longer hospitalization, higher mortality, and increased health-related costs. However, the frequency, risk factors and predictive biomarkers of this comorbidity in pediatric dengue is partially known. Methods: We conducted a retrospective multicenter study in a dengue hyperendemic region of Colombia, analyzing 1597 children from two pediatric cohorts. We included children with confirmed dengue (mild to severe disease) and evaluated the rate of SBI, their clinical characteristics, diagnostic predictors and attention costs. We also assessed the diagnostic performance of plasma interleukin (IL)-6 for detecting SBI in pediatric dengue. Results: The frequency of SBI in children with dengue with warning signs in cohorts 1 and 2 was 2.4% and 7.3%, respectively, and this rate reached 30.7% and 38.2% in children with severe disease. Staphylococcus aureus and Escherichia coli were the more frequent infectious agents. Increased total leukocytes and C-reactive protein levels, as well as high IL-6 at hospital admission, in children <48 months of age were early indications of SBI in dengue. Higher rates of organ dysfunction, the requirement of a longer hospitalization and a 2.3-fold increase in attention costs were observed in SBI. Conclusions: An important proportion of children with dengue course with SBI and exhibit higher morbidity. Elevated leukocytes, C-reactive protein and IL-6 in young children are early markers of SBI. Physicians should identify children with dengue and risk factors for SBI, microbiologically confirm the bacterial infection, and rationally and timely provide antimicrobial therapy.


  • Open Access

    Recent advances in CD8+ T cell-based immune therapies for HIV cure

    by Valentina Restrepo Arenas, María T. Rugeles, Federico Perdomo-Celis, Natalia Taborda